Diagnostic and prognostic performance of a novel high-sensitivity cardiac troponin T assay compared to a contemporary sensitive cardiac troponin I assay in patients with acute coronary syndrome

被引:52
作者
Mueller, M. [1 ]
Celik, S. [1 ]
Biener, M. [1 ]
Vafaie, M. [1 ]
Schwoebel, K. [1 ]
Wollert, K. C. [2 ]
Januzzi, J. L. [3 ]
Katus, H. A. [1 ]
Giannitsis, E. [1 ]
机构
[1] Univ Klinikum Heidelberg, Med Klin, Abt Innere Med 3, D-69120 Heidelberg, Germany
[2] Hannover Med Sch, Klin Kardiol & Angiol, D-30623 Hannover, Germany
[3] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA
关键词
High-sensitivity troponin; Acute coronary syndrome; Prognosis; Early diagnosis; ELEVATION MYOCARDIAL-INFARCTION; EARLY INVASIVE STRATEGY; CLINICAL-PERFORMANCE; 99TH PERCENTILE; ARTERY DISEASE; RISK; OUTCOMES; TRIAL;
D O I
10.1007/s00392-012-0469-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The study sought to compare the clinical performance of two more sensitive cardiac troponin (cTn) assays, a novel high-sensitivity (hs) troponin T assay and a contemporary cTnI assay. We measured hs-cTnT (Roche TnThs) and cTnI (Siemens Centaur Ultra) on presentation in 1,384 patients with suspected acute coronary syndrome (ACS) who underwent early invasive strategy within 24 h after presentation. Kaplan-Meier, Cox proportional hazards, and receiver-operating characteristic (ROC) analysis was used to compare their prognostic performance for the prediction of all-cause death and death/MI (myocardial infarction) after a median of 271 days. We also compared the diagnostic performance of these assays on presentation for early diagnosis of non-STEMI. Both hs-cTnT and cTnI were independently predictive of long-term death (OR 3.51 vs. 2.19) and the composite of death/MI (OR 9.24 vs. 3.61), across the spectrum of ACS and in patients without ACS. When used as a continuous variable, ROC analysis demonstrated significantly higher areas under the curve (AUC) for hs-cTnT as compared to cTnI for the prediction of death/MI (0.721 vs. 0.672, P = 0.024), a trend to better prediction of all-cause death (0.721 vs. 0.672, P = 0.093) and significantly higher AUC for early diagnosis of non-STEMI (0.965 vs. 0.901, P < 0.001). Using the 99th percentile cutoff for hs-cTnT and cTnI, both assays enable prediction of adverse long-term outcomes and earlier diagnosis of non-STEMI. Used as a continuous variable, the hs-cTnT assay showed superior performance compared to the cTnI assay, especially in regard to prognosis.
引用
收藏
页码:837 / 845
页数:9
相关论文
共 23 条
[1]   Use of the centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome [J].
Apple, Fred S. ;
Smith, Stephen W. ;
Pearce, Lesly A. ;
Ler, Ranka ;
Murakami, MaryAnn M. .
CLINICAL CHEMISTRY, 2008, 54 (04) :723-728
[2]   A New Season for Cardiac Troponin Assays: It's Time to Keep a Scorecard [J].
Apple, Fred S. .
CLINICAL CHEMISTRY, 2009, 55 (07) :1303-1306
[3]   Cardiac troponin T concentrations above the 99th percentile value as measured by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary syndromes undergoing routine early invasive strategy [J].
Celik, S. ;
Giannitsis, E. ;
Wollert, K. C. ;
Schwoebel, K. ;
Lossnitzer, D. ;
Hilbel, T. ;
Lehrke, S. ;
Zdunek, D. ;
Hess, A. ;
Januzzi, J. L. ;
Katus, H. A. .
CLINICAL RESEARCH IN CARDIOLOGY, 2011, 100 (12) :1077-1085
[4]   Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making [J].
Eggers, Kai M. ;
Jaffe, Allan S. ;
Lind, Lars ;
Venge, Per ;
Lindahl, Bertil .
CLINICAL CHEMISTRY, 2009, 55 (01) :85-92
[5]   High-Sensitivity Cardiac Troponin T for Early Prediction of Evolving Non-ST-Segment Elevation Myocardial Infarction in Patients with Suspected Acute Coronary Syndrome and Negative Troponin Results on Admission [J].
Giannitsis, Evangelos ;
Becker, Meike ;
Kurz, Kerstin ;
Hess, Georg ;
Zdunek, Dietmar ;
Katus, Hugo A. .
CLINICAL CHEMISTRY, 2010, 56 (04) :642-650
[6]   Analytical Validation of a High-Sensitivity Cardiac Troponin T Assay [J].
Giannitsis, Evangelos ;
Kurz, Kerstin ;
Hallermayer, Klaus ;
Jarausch, Jochen ;
Jaffe, Allan S. ;
Katus, Hugo A. .
CLINICAL CHEMISTRY, 2010, 56 (02) :254-261
[7]  
Giannitsis E, 2009, HERZ, V34, P600, DOI 10.1007/s00059-009-3306-6
[8]   Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: Prospective verification in the GUSTO-IV trial [J].
James, S ;
Armstrong, P ;
Califf, R ;
Simoons, ML ;
Venge, P ;
Wallentin, L ;
Lindahl, B .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 (03) :178-184
[9]   Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial [J].
Kastrati, A ;
Mehilli, J ;
Neumann, FJ ;
Dotzer, F ;
ten Berg, JN ;
Bollwein, H ;
Graf, I ;
Ibrahim, M ;
Pache, J ;
Seyfarth, M ;
Schühlen, H ;
Dirschinger, J ;
Berger, PB ;
Schömig, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1531-1538
[10]   Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population [J].
Kavsak, Peter A. ;
Wang, Xuesong ;
Ko, Dennis T. ;
MacRae, Andrew R. ;
Jaffe, Allan S. .
CLINICAL CHEMISTRY, 2009, 55 (10) :1809-1815